GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Cash-to-Debt

Ocugen (Ocugen) Cash-to-Debt : 5.69 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ocugen's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ocugen could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ocugen's Cash-to-Debt or its related term are showing as below:

OCGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.29   Med: 25.86   Max: No Debt
Current: 5.69

During the past 12 years, Ocugen's highest Cash to Debt Ratio was No Debt. The lowest was 5.29. And the median was 25.86.

OCGN's Cash-to-Debt is ranked worse than
52.08% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs OCGN: 5.69

Ocugen Cash-to-Debt Historical Data

The historical data trend for Ocugen's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ocugen Cash-to-Debt Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.29 9.65 28.72 14.27 5.69

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.27 12.23 10.74 8.26 5.69

Competitive Comparison of Ocugen's Cash-to-Debt

For the Biotechnology subindustry, Ocugen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ocugen's Cash-to-Debt falls into.



Ocugen Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ocugen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Ocugen's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocugen  (NAS:OCGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Ocugen Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ocugen's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (Ocugen) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355